Leveraging up to date insights from the competive landscape and health technology assessment decisions across 19 agencies in 11 counties.
A leading pharmaceutical company
Name of service provided
Adapting evidence generation strategy in line with the rapidly evolving payer and HTA landscape
When launching their latest immunotherapy for a fast-evolving indication, our client sought an in-depth understanding of the latest payer thinking across global markets. In order to do this, the client required a digital application that could track the healthcare technology assessment (HTA) landscape and interpret outcomes and agency criticisms, give a global overview of the rapidly evolving payer landscape and leverage information to give strategic insights from competitor assessments and recommendations for their asset.
The client leveraged the PRMA Tracker® to develop a cumulative summary of more than 300 health technology assessment decisions, so they could focus their evidence development activities. This enabled them to understand the competitive landscape, payer expectations, appropriate comparators, and value perception
Timely alerts about HTA decisions helped accelerate the development of effective strategies. Efficiency and collaboration were enhanced by introducing a single source of landscape assessments, including clinical and economic data packages from competitors, HTA decisions, and critical analysis across all markets.
The PRMA Tracker® enabled the client to anticipate evidence needs early on, and discussions with the our market access experts helped drive evidence development activities. Through access to the PRMA Tracker®, the client gained insight into the dynamic HTA landscape and was able to leverage this for the indication and discussions of the implications for their product. This enabled the client to adapt their evidence-generation strategy to reduce the risk of unforeseen HTA objections and allowed time to develop strategies to mitigate risks.